![Cyclacel Reports Phase 2 Survival Data with Sapacitabine](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![Cyclacel Reports Phase 2 Survival Data with Sapacitabine](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
Cyclacel Reports Phase 2 Survival Data with Sapacitabine
Biotech Business 2011, Jan 1, 24, 1
-
- $5.99
-
- $5.99
Publisher Description
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) Berkeley Heights, N.J. has announced 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. "MDS patients have a poor outcome after treatment failures of hypomethylating agents. Effective therapies are urgently needed to improve the survival of these patients," said Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas and study chair of the sapacitabine Phase 2 study. "The survival data of sapacitabine in this study are promising and warrant further clinical development in this patient population."